Humana Inc. (NYSE:HUM) had its price target lifted by Deutsche Bank AG from $234.00 to $243.00 in a report published on Monday, August 7th. Deutsche Bank AG currently has a hold rating on the insurance provider’s stock.
A number of other analysts have also recently weighed in on HUM. Jefferies Group LLC reissued a hold rating and set a $257.00 target price on shares of Humana in a report on Friday, August 4th. Cantor Fitzgerald reissued a neutral rating and set a $223.00 target price (up from $200.00) on shares of Humana in a report on Thursday, August 3rd. Oppenheimer Holdings, Inc. increased their target price on shares of Humana from $236.00 to $255.00 and gave the stock an outperform rating in a report on Thursday, August 3rd. Credit Suisse Group reissued an outperform rating and set a $260.00 target price (up from $250.00) on shares of Humana in a report on Thursday, August 3rd. Finally, Piper Jaffray Companies increased their target price on shares of Humana to $280.00 and gave the stock an overweight rating in a report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $244.35.
Shares of Humana (NYSE HUM) traded down 0.15% during trading on Monday, reaching $247.28. 754,398 shares of the company’s stock traded hands. The stock has a 50-day moving average of $241.05 and a 200-day moving average of $224.57. The company has a market capitalization of $35.74 billion, a price-to-earnings ratio of 20.34 and a beta of 0.91. Humana has a 1-year low of $163.50 and a 1-year high of $255.27.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the prior year, the firm posted $2.30 EPS. On average, equities analysts predict that Humana will post $11.55 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/humana-inc-hum-price-target-raised-to-243-00-at-deutsche-bank-ag-updated.html.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Tuesday, August 29th will be given a $0.40 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a yield of 0.65%. Humana’s dividend payout ratio is presently 13.06%.
In other news, VP Heidi S. Margulis sold 1,500 shares of the firm’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the completion of the transaction, the vice president now owns 8,150 shares in the company, valued at approximately $1,890,474. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,406 shares of company stock valued at $10,355,086. Insiders own 0.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of HUM. Baldwin Brothers Inc. MA raised its position in Humana by 2.7% in the first quarter. Baldwin Brothers Inc. MA now owns 67,441 shares of the insurance provider’s stock valued at $13,902,000 after buying an additional 1,782 shares during the period. Creative Planning raised its position in Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after buying an additional 15 shares during the period. ProShare Advisors LLC raised its position in Humana by 15.8% in the first quarter. ProShare Advisors LLC now owns 17,297 shares of the insurance provider’s stock valued at $3,566,000 after buying an additional 2,356 shares during the period. Capstone Asset Management Co. raised its position in Humana by 2.0% in the first quarter. Capstone Asset Management Co. now owns 16,805 shares of the insurance provider’s stock valued at $3,464,000 after buying an additional 334 shares during the period. Finally, US Bancorp DE raised its position in Humana by 4.4% in the second quarter. US Bancorp DE now owns 44,359 shares of the insurance provider’s stock valued at $10,674,000 after buying an additional 1,870 shares during the period. Institutional investors own 99.13% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.